| ID | 10088 |
| Vaccine Name | Weisairuiji Biovac-A Mevac-A |
| Disease Name | Hepatitis A |
| Disease Classification | Hepatitic |
| Virus Name | Hepatitis A virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Approved |
| Manufacturer | Biogenetech Co. Ltd., Zhejiang Pukang Biotechnology Co. Ltd. |
| Year of Manufacturing | 2010 |
| Manufacturing Country | Thailand |
| Age | 1.5 years and above |
| Dosage | Single dose |
| Administration Route | Subcutaneous |
| Adjuvant | NA |
| Target Strain | H2 strain of HAV |
| Description | H2-attenuated strain of HAV cultured in human diploid cells. |
| Approving Organisation | China FDA, US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | MEVAC-A |
| PMID | 24280971 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/ |
| Additional Links | https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf
|